LENZ Therapeutics, Inc. (LENZ) Stock

Healthcare · Biotechnology · Member of Other US Stocks

LENZ Therapeutics, Inc. (LENZ) closed at USD 3.43 on 2026-10-14, a change of -88.9 % over the past year, with a market capitalization of USD 112.17M.

LENZ Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

LENZ Therapeutics, Inc. key figures

Previous close

USD 3.43 (2026-10-14)

1-year change

-88.9 %

Market cap

USD 112.17M

Enterprise value

USD -107.26M

P/E ratio (trailing)

-0.82

P/E ratio (forward)

-1.23

EPS (trailing)

-4.35

EPS (forward)

-2.91

PEG ratio

n/a

Price to book

0.51

Revenue growth

9.7 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

13.99

Employees

152

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About LENZ Therapeutics, Inc.

LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for LENZ Therapeutics, Inc. and compare it with other stocks.